Terms: = Ovarian cancer AND WFDC2, EDDM4, HE4, WAP5, dJ461P17.6 AND Treatment
127 results:
1. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of prediction model for early warning of ovarian metastasis risk of endometrial carcinoma.
Zhao Q; Li Y; Wang T
Medicine (Baltimore); 2023 Oct; 102(41):e35439. PubMed ID: 37832099
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer.
Tan X; Zou S; Chen H; Chen D
J Int Med Res; 2023 Sep; 51(9):3000605231200267. PubMed ID: 37756606
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic value of CA125, he4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses.
Song L; Qi J; Zhao J; Bai S; Wu Q; Xu R
Medicine (Baltimore); 2023 Sep; 102(37):e35240. PubMed ID: 37713838
[TBL] [Abstract] [Full Text] [Related]
5. [
Chen J; Xu K; Li C; Tian Y; Li L; Wen B; He C; Cai H; He Y
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4064-4076. PubMed ID: 37526694
[TBL] [Abstract] [Full Text] [Related]
6. Mucinous cystadenocarcinoma of the ovary in a 14-year-old girl: a case report and literature review.
Li Q; Zou C; Xu Y; Liu S; Yan T
BMC Womens Health; 2023 Jul; 23(1):382. PubMed ID: 37479970
[TBL] [Abstract] [Full Text] [Related]
7. Mass Spectrometry-Based Proteomics of Epithelial ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
8. Sensitive Detection of the Human Epididymis Protein-4 (he4) ovarian cancer Biomarker through a Sandwich-Type Immunoassay Method with Laser-Induced Breakdown Spectroscopy.
Karunanithy R; Ratnasingam S; Holland T; Sivakumar P
Bioconjug Chem; 2023 Mar; 34(3):501-509. PubMed ID: 36762387
[TBL] [Abstract] [Full Text] [Related]
9. Measurement of he4 six months after first-line treatment as optimal time in identifying patients at high risk of progression advanced ovarian cancer.
Kotowicz BU; Fuksiewicz M; Bidzinski M; Berezowska A; Sobiczewski P; Kowalska MM
Ginekol Pol; 2022; 93(11):910-915. PubMed ID: 36621970
[TBL] [Abstract] [Full Text] [Related]
10. he4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer.
Samborski A; Miller MC; Blackman A; MacLaughlan-David S; Jackson A; Lambert-Messerlian G; Rowswell-Turner R; Moore RG
Tumour Biol; 2022; 44(1):205-213. PubMed ID: 36189508
[TBL] [Abstract] [Full Text] [Related]
11. CT imaging phenotypes linked to CA125 and he4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.
Manganaro L; Celli V; Viggiani V; Berardelli E; Granato T; Tartaglione S; Farina A; Catalano C; Angeloni A; Anastasi E
Tumour Biol; 2022; 44(1):171-185. PubMed ID: 36093649
[TBL] [Abstract] [Full Text] [Related]
12. Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent ovarian Epithelial Carcinoma.
Sun L; Liu C; Li Y
Comput Math Methods Med; 2022; 2022():4600145. PubMed ID: 35720032
[TBL] [Abstract] [Full Text] [Related]
13. [Establishment and application of a nomogram model for prognostic risk prediction in patients with epithelial ovarian cancer].
Li Z; Cai XW; Yan P; Zhou D; He MM; Deng L; Wang YZ; Liang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2022 Mar; 57(3):190-197. PubMed ID: 35385956
[No Abstract] [Full Text] [Related]
14. Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced ovarian cancer and the Effect on the Levels of Serum Markers VEGF, he4, and CA125.
Wang N; Xiao F; Shao H; Shi S; Zhou Y
J Healthc Eng; 2022; 2022():8401202. PubMed ID: 35368946
[TBL] [Abstract] [Full Text] [Related]
15. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
Chen W; Shan B; Zhou S; Yang H; Ye S
BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
[TBL] [Abstract] [Full Text] [Related]
16. Targeting and neutralizing human epididymis protein 4 by novel nanobodies to suppress ovarian cancer cells and attenuate cisplatin resistance.
Yu J; Guo Y; Gu Y; Li F; Song H; Nian R; Fan X; Liu W
Int J Biol Macromol; 2022 Feb; 199():298-306. PubMed ID: 35016970
[TBL] [Abstract] [Full Text] [Related]
17. Nomogram of Combining CT-Based Body Composition Analyses and Prognostic Inflammation Score: Prediction of Survival in Advanced Epithelial ovarian cancer Patients.
Wang X; Zhang C; Cao F; Wang CB; Dong JN; Wang ZH
Acad Radiol; 2022 Sep; 29(9):1394-1403. PubMed ID: 34955366
[TBL] [Abstract] [Full Text] [Related]
18. A prediction model based on clinical and histological features for predicting recurrence in patients with stage I-II endometrial cancer after surgical treatment.
Song W; Zhao Y
Ann Diagn Pathol; 2022 Feb; 56():151861. PubMed ID: 34953233
[TBL] [Abstract] [Full Text] [Related]
19. Past, Present, and Future of Serum Tumor Markers in Management of ovarian cancer: A Guide for the Radiologist.
Rao S; Smith DA; Guler E; Kikano EG; Rajdev MA; Yoest JM; Ramaiya NH; Tirumani SH
Radiographics; 2021 Oct; 41(6):1839-1856. PubMed ID: 34597221
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [
Glickman A; Paredes P; Carreras-Diéguez N; Niñerola-Baizán A; Gaba L; Pahisa J; Fusté P; Del Pino M; Díaz-Feijóo B; González-Bosquet E; Agustí N; Sánchez-Izquierdo N; Fuster D; Perissinotti A; Romero I; Fernández-Galán E; Carrasco JL; Gil-Ibáñez B; Torné A
Eur Radiol; 2022 Apr; 32(4):2200-2208. PubMed ID: 34586465
[TBL] [Abstract] [Full Text] [Related]
[Next]
